Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies

Abhishek Jaiswal1, Seth Goldbarg1

  • 1Division of Cardiology, New York Hospital Queens/Weill Medical College of Cornell University, Flushing, NY 11355, USA.

Indian Heart Journal
|January 31, 2015
PubMed

Insights

Dofetilide effectively treats atrial fibrillation but carries a risk of proarrhythmia. Strict adherence to dosing guidelines minimizes the risk of torsades de pointes (Tdp) when using this antiarrhythmic drug.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dofetilide is an effective antiarrhythmic medication for atrial fibrillation and flutter.
  • Proarrhythmia, including torsades de pointes (Tdp), is a known adverse effect of dofetilide.
  • Risk of Tdp is minimized with strict dosing based on renal function, QT interval, and drug interactions.

Purpose of the Study:

  • To review the mechanism, risk factors, and prevention of dofetilide-induced QT prolongation and Tdp.
  • To outline a management strategy for QT prolongation, ventricular arrhythmia, and Tdp.

Main Methods:

  • Literature review of dofetilide's antiarrhythmic properties and adverse effects.
  • Analysis of risk factors contributing to QT prolongation and Tdp.
  • Development of a clinical management scheme.

Main Results:

  • Dofetilide efficacy in rhythm conversion and maintenance is established.
  • Proarrhythmia risk is significantly reduced by individualized dosing and monitoring.
  • Clear guidelines for managing adverse events are crucial.

Conclusions:

  • Dofetilide offers significant benefits for selected patients with atrial arrhythmias.
  • Careful patient selection and adherence to dosing protocols are paramount to safety.
  • A structured approach to managing QT prolongation and Tdp enhances patient outcomes.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.3K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
640
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
798